The trial is taking place at:
O

Optimed Research, LTD | Optimed Research, LTD

Veeva-enabled site

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (HAErmony-1)

BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

Status and phase

Active, not recruiting
Phase 2
Phase 1

Conditions

HAE
Hereditary Angioedema

Treatments

Genetic: Dose 6 of BMN 331
Genetic: Dose 2 of BMN 331
Genetic: Dose 1 of BMN 331
Genetic: Dose 3 of BMN 331
Genetic: Dose 4 of BMN 331
Genetic: Dose 7 of BMN 331
Genetic: Dose 5 of BMN 331

Study type

Interventional

Funder types

Industry

Identifiers

NCT05121376
331-201

Details and patient eligibility

About

This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficiency. The pharmaceutical form of BMN 331 is a solution for intravenous infusion.

Full description

BMN 331 is an investigational, single administration gene therapy intended to modify the disease course of HAE. Preclinical studies have shown that BMN 331 can transduce hepatocytes resulting in restoration of the deficient circulating levels of hC1-INH that cause HAE. Study 331-201 is a two-part (part A and part B), first-in-human, Phase 1/2 study designed to assess the safety and efficacy of BMN 331 in patients with HAE. Subjects will be followed for 5 years following BMN 331 infusion. Part A of the study is a dose escalation phase designed to assess the preliminary safety of a single IV administration of BMN 331 and to determine whether there is a dose-dependent increase in C1-INH protein expression following administration of BMN 331. Part B is a dose expansion phase designed to demonstrate that up to three safe doses of BMN 331 (as determined in Part A) sustains a clinically meaningful increase in C1-INH levels.

Enrollment

44 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female or male adults ( ≥ 18 years old)
  • Part A only: Confirmed diagnosis of Type I HAE due to C1-INH deficiency confirmed by genotyping of the SERPING1 gene Part B only: Confirmed diagnosis of Type I or II HAE due to C1-INH deficiency confirmed by genotyping of the SERPING1 gene
  • Currently using an HAE medication regimen that consists of a routine long-term prophylactic treatment for at least 6 months prior to enrollment or an on-demand therapy regimen for a documented attack frequency of at least 4 attacks within the last 12 months prior to enrollment or at least 2 attacks within the last 6 months prior to enrollment
  • Trained in self-administering acute attack treatment and is able to adequately manage acute attacks in a home setting
  • Willingness to abstain from consumption of alcohol for at least 52 weeks post BMN 331 infusion and to use highly effective contraception

Exclusion criteria

  • Evidence of active or chronic infection, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or any immunosuppressive disorder
  • Contraindication to using glucocorticosteroids GCS, including a diagnosis of glaucoma or untreated osteoporosis
  • Active malignancy (except non-melanoma skin cancer) autoimmune, metabolic (i.e., diabetes), hematologic, cardiac, or renal disease that is of clinical significance defined as requiring regular medical attention and treatment
  • Prior gene therapy treatment
  • Prior use of high-dose attenuated androgens in the last 1 year prior to the study
  • History or current clinically relevant liver disease (eg, nonalcoholic steatohepatitis [NASH], or chronic viral hepatitis B or C [HBV or HCV] or autoimmune hepatitis)
  • Have a history or are at risk for clinically significant thromboembolic events (TEE) , or known underlying risk factor for thrombosis including thrombotic microangiopathy (TMA)

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Sequential Assignment

Masking

None (Open label)

44 participants in 1 patient group

BMN 331
Experimental group
Description:
AAV Gene Therapy Infusion
Treatment:
Genetic: Dose 7 of BMN 331
Genetic: Dose 5 of BMN 331
Genetic: Dose 4 of BMN 331
Genetic: Dose 3 of BMN 331
Genetic: Dose 1 of BMN 331
Genetic: Dose 2 of BMN 331
Genetic: Dose 6 of BMN 331

Trial contacts and locations

16

Loading...

Central trial contact

Trial Specialist

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems